A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).

MLA

Yong Jae Lee, et al. “A Single-Arm Phase II Study of Olaparib Maintenance with Pembrolizumab and Bevacizumab in BRCA Non-Mutated Patients with Platinum-Sensitive Recurrent Ovarian Cancer (OPEB-01).” Journal of Gynecologic Oncology, vol. 32, no. 2, Mar. 2021, pp. 1–7. EBSCOhost, https://doi.org/10.3802/jgo.2021.32.e31.

APA

Yong Jae Lee, Myong Cheol Lim, Byoung-Gie Kim, Chel Hun Choi, Sang-Yoon Park, Tan, D. S. P., Yunjung Go, & Jung-Yun Lee. (2021). A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). Journal of Gynecologic Oncology, 32(2), 1–7. https://doi.org/10.3802/jgo.2021.32.e31

Chicago

Yong Jae Lee, Myong Cheol Lim, Byoung-Gie Kim, Chel Hun Choi, Sang-Yoon Park, David S. P. Tan, Yunjung Go, and Jung-Yun Lee. 2021. “A Single-Arm Phase II Study of Olaparib Maintenance with Pembrolizumab and Bevacizumab in BRCA Non-Mutated Patients with Platinum-Sensitive Recurrent Ovarian Cancer (OPEB-01).” Journal of Gynecologic Oncology 32 (2): 1–7. doi:10.3802/jgo.2021.32.e31.